At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 9, 2026 at 16:26 ET
Trevi Therapeutics reported a Q3 2026 net loss of $21.5 million, wider than the $11.8 million loss in Q3 2025, driven by increased R&D spending on Phase 3 OCEAN trials. The company highlighted FDA alignment on the non-IPF ILD program, initiation of the Phase 3 OCEAN-2 trial, and a USPTO Notice of Allowance extending patent protection to 2041. Cash runway into 2030 supports key milestones.
- Q3 2026 net loss of $21.5 million vs $11.8 million in Q3 2025
- Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026
- Phase 3 OCEAN-2 trial initiated in Q3 2026; both OCEAN trials actively recruiting
- Positive FDA meeting on non-IPF ILD program; Phase 2 dose-ranging trial expected Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access